FOSTER CITY, Calif
The FDA approved sofosbuvir on December 6, 2013 and it is indicated for the treatment of chronic hepatitis C genotype 1, 2, 3, or 4 infection in adult patients without cirrhosis or with FDA Approves Gilead's Sovaldi, First Interferon-sparing HCV Therapy Jan 1, 2014 In December 2013, the US Food and Drug Administration (FDA) approved Sovaldi
The Food and Drug Administration has approved the use of Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) for the treatment of hepatitis C virus
However, it’s only approved for use in
We have completed our
SOVALDI®(sofosbuvir) tablets, for oral use SOVALDI®(sofosbuvir) oral pellets Initial U